Silence Therapeutics combines explosive revenue growth and an engine-favored asymmetric setup with severe cash burn and volatile earnings, making it a high-risk, high-reward growth story.
Thesis pillars
- Extreme Cash Burn Rule Of 40 Fail→Stable
- Explosive Revenue Growth→Stable
- Overbought Momentum Asymmetric Upside→Stable
- +2 more pillars — see the Why tab for full reasoning
Silence Therapeutics Plc - Amer (SLN) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $10.13: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.6/10 and A.R:R 9.6:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 5.50; Below-average business quality.
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The... Read more
Sell if holding. Engine safety override at $10.13: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.6/10 and A.R:R 9.6:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 5.50; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.6/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 33d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·2 ceiling hits
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $10.13: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.6/10 and A.R:R 9.6:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 5.50; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $9.66. Score 6.6/10, moderate confidence.
Take-profit target: $25.38 (+144.3% upside). Prior stop was $9.66. Stop-loss: $9.66.
Quality below floor (3.5 < 4.0).
Silence Therapeutics Plc - Amer trades at a P/E of N/A (forward -26.6). TrendMatrix value score: 9.0/10. Verdict: Sell.
What does Silence Therapeutics Plc - Amer do?Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules...
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.